JP7026299B2 - Tg02によるがん治療 - Google Patents

Tg02によるがん治療 Download PDF

Info

Publication number
JP7026299B2
JP7026299B2 JP2019500752A JP2019500752A JP7026299B2 JP 7026299 B2 JP7026299 B2 JP 7026299B2 JP 2019500752 A JP2019500752 A JP 2019500752A JP 2019500752 A JP2019500752 A JP 2019500752A JP 7026299 B2 JP7026299 B2 JP 7026299B2
Authority
JP
Japan
Prior art keywords
cancer
patient
cell
tumor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509354A5 (cg-RX-API-DMAC7.html
JP2019509354A (ja
Inventor
トーマス エム. エストック
エッカード ウェバー
トレイシー パロット
Original Assignee
コセラ バイオサイエンス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コセラ バイオサイエンス, インコーポレイテッド filed Critical コセラ バイオサイエンス, インコーポレイテッド
Publication of JP2019509354A publication Critical patent/JP2019509354A/ja
Publication of JP2019509354A5 publication Critical patent/JP2019509354A5/ja
Priority to JP2022004776A priority Critical patent/JP7459149B2/ja
Application granted granted Critical
Publication of JP7026299B2 publication Critical patent/JP7026299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019500752A 2016-03-24 2017-03-24 Tg02によるがん治療 Active JP7026299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022004776A JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662312712P 2016-03-24 2016-03-24
US62/312,712 2016-03-24
US201662423468P 2016-11-17 2016-11-17
US62/423,468 2016-11-17
PCT/US2017/023965 WO2017165732A1 (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022004776A Division JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Publications (3)

Publication Number Publication Date
JP2019509354A JP2019509354A (ja) 2019-04-04
JP2019509354A5 JP2019509354A5 (cg-RX-API-DMAC7.html) 2020-05-07
JP7026299B2 true JP7026299B2 (ja) 2022-02-28

Family

ID=59899752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019500752A Active JP7026299B2 (ja) 2016-03-24 2017-03-24 Tg02によるがん治療
JP2022004776A Active JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022004776A Active JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Country Status (12)

Country Link
US (2) US11865116B2 (cg-RX-API-DMAC7.html)
EP (1) EP3432888B1 (cg-RX-API-DMAC7.html)
JP (2) JP7026299B2 (cg-RX-API-DMAC7.html)
KR (2) KR102491013B1 (cg-RX-API-DMAC7.html)
CN (2) CN115969854B (cg-RX-API-DMAC7.html)
AU (1) AU2017238647B2 (cg-RX-API-DMAC7.html)
ES (1) ES2941687T3 (cg-RX-API-DMAC7.html)
IL (1) IL261959B2 (cg-RX-API-DMAC7.html)
MX (3) MX2021012977A (cg-RX-API-DMAC7.html)
RU (1) RU2749025C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202005621WA (cg-RX-API-DMAC7.html)
WO (1) WO2017165732A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
MX2021011301A (es) * 2019-03-18 2022-01-19 Univ Texas Terapia combinada especifica contra tumores.
ES3034869T3 (en) * 2019-04-22 2025-08-25 Univ Pittsburgh Commonwealth Sys Higher Education Tg02 for use in treating gliomas in pediatric subjects
WO2021155580A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating cancer
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
WO2022035723A1 (en) * 2020-08-10 2022-02-17 The Broad Institute, Inc. Compositions, panels, and methods for characterizing chronic lymphocytic leukemia
MX2024006078A (es) * 2021-11-18 2024-08-09 Lantern Pharma Inc Metodo para tratar el cancer con acilfulveno y radiacion.
CN114113051B (zh) * 2021-12-16 2023-06-16 南京信息工程大学 一种psma电致化学发光传感器的制备方法及应用
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN114480639B (zh) * 2021-12-24 2022-09-30 中国医学科学院北京协和医院 新靶点用于诊断和治疗垂体腺瘤
WO2023143608A1 (zh) * 2022-01-30 2023-08-03 上海复东生物医药有限责任公司 一种组合物、其制备方法及应用
CN114518456B (zh) * 2022-02-17 2025-06-20 南京医科大学 一种通过diaph1蛋白预测肿瘤免疫治疗疗效的方法及试剂盒
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
US9120815B2 (en) * 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
WO2014011695A2 (en) * 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014161046A1 (en) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Methods of treating diseases characterized by excessive wnt signalling
CN105473581B (zh) * 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
US11013743B2 (en) * 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
US10383873B2 (en) * 2014-04-04 2019-08-20 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Blood,2015年,Vol.126,No.23,p.3052
Cancer Research,Vol.71,No.Suppl.8,2011年,p.2487
Clin.Cancer Res.,Vol.19,No.10,2013年,pp.2677-2687
Journal of Clinical Oncology,2011年,Vol.28,No.15, Supp. SUPPL.1,Abstract Number:e13549
Proceedings of the American Association for Cancer Research Annual Meeting,Vol.47,2006年,p.1097

Also Published As

Publication number Publication date
EP3432888B1 (en) 2022-10-05
MX387283B (es) 2025-03-18
CA3018875A1 (en) 2017-09-28
KR20190006948A (ko) 2019-01-21
RU2749025C2 (ru) 2021-06-03
IL261959B1 (en) 2023-04-01
IL261959A (en) 2018-10-31
WO2017165732A1 (en) 2017-09-28
JP7459149B2 (ja) 2024-04-01
AU2017238647B2 (en) 2021-12-09
SG10202005621WA (en) 2020-07-29
RU2018137217A3 (cg-RX-API-DMAC7.html) 2020-05-29
US11865116B2 (en) 2024-01-09
CN115969854B (zh) 2025-12-23
SG11201808306PA (en) 2018-10-30
MX2021012977A (es) 2022-10-03
RU2018137217A (ru) 2020-04-24
ES2941687T3 (es) 2023-05-24
JP2019509354A (ja) 2019-04-04
MX2022008868A (es) 2022-08-11
AU2017238647A1 (en) 2018-10-25
JP2022050631A (ja) 2022-03-30
EP3432888A1 (en) 2019-01-30
IL261959B2 (en) 2023-08-01
EP3432888A4 (en) 2019-11-13
NZ746933A (en) 2025-03-28
KR102491013B1 (ko) 2023-01-31
US20200323862A1 (en) 2020-10-15
CN115969854A (zh) 2023-04-18
CN109195603B (zh) 2022-11-08
CN109195603A (zh) 2019-01-11
US20240156824A1 (en) 2024-05-16
KR20230020549A (ko) 2023-02-10

Similar Documents

Publication Publication Date Title
JP7459149B2 (ja) Tg02によるがん治療
JP2022536728A (ja) アミノ酸輸送阻害剤としてのジベンジルアミン類
US20220304984A1 (en) Amino acid transport inhibitors and the uses thereof
TWI785098B (zh) Tg02之多晶型
Wang et al. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer
CN107613969B (zh) 对使用维甲酸受体-α激动剂治疗的患者进行分层的方法
JP7442439B2 (ja) Kdm4阻害剤
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
WO2022094058A1 (en) Methods for preventing or treating conditions related to pikfyve activity
US20240174658A1 (en) Heteroaromatic Inhibitors of Cancer Metabolism
TWI781510B (zh) 專一性抑制泛素特異性胜肽酶24、延緩或逆轉癌症多重抗藥性的醫藥組成物
WO2022140661A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
Fontão Embryonic T-Box Transcription Factor Brachyury as a Predictive Biomarker and Therapeutic Target in Prostate and Lung Cancers
Morfouace et al. MEDULLOBLASTOMA
HK40030306A (en) Polymorphic form of tg02

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211214

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220119

R150 Certificate of patent or registration of utility model

Ref document number: 7026299

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250